reason report
strong new product add old profit increas
result beat consensu estim revenu ep
driven strong symdeko uptak us less eros orkambi
still robust kalydeco revenu expens lower expect
result beat vs consensu beat compar
estim revenu grew yoy sequenti
ep increas compar period prior year
compani continu shift investor attent toward non-cf
pipelin sever chang lead compound leav market
confus whether count prospect timelin
program base quarter stronger expect
result increas target price reiter
marketperform rate vertex stock
total cystic fibrosi cf product revenu beat
consensu estim grow yoy
sequenti due strong uptak label expans
newer symdeko establish orkambi combin therapi
manag commentari suggest treatment penetr
us adult homozyg cystic fibrosi cf patient
kalydeco-lik highlight near-univers adopt combin
achiev reimburs avail base strong
quarter product sale compani rais full year product revenu
guidanc higher
prior estim consensu non-gaap
 sg expens quarter compar
consensu manag expens
guidanc year unchang
high end rang approxim estim
consensu compani see significantli
revenu growth next year tripl combin launch
even broader label indic symdeko much
profound efficaci continu expect eu approv tripl
like could trigger widespread
reimburs whole portfolio still-resist market
uk franc
cf revenu forecast increas base strong trend price
target increas updat revenu expens
forecast base recent quarter commentari total
revenu forecast increas remain larg
unchang increas forecast
average ep revenu multipl
dcf wacc tg
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep dilut exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
symdeko rel short term model
transit tripl combin signific increment revenu
mid continu forecast total revenu grow
year revis forecast
consensu later year base
compani burgeon develop portfolio increas
 forecast year beyond result total
oper expens forecast increas
later year adjust share count forecast compani
newli announc small share repurchas base chang
pro-forma dilut ep estim significantli increas year
materi recent consensu
estim higher recent consensu
later year estim larg unchang significantli
recent consensu revis price target
maintain market perform rate vrtx stock
price target vertex rate stock market perform vertex
clear clinic develop hurdl introduc medicin treat
patient cystic fibrosi cf believ market fairli valu vertex cf
portfolio loss exclus vertex launch success iter cf
medicin cloud disput price access delay reimburs
europ result success reduct revenu forecast compani
expect vertex cf revenu line grow steadili
consensu expect still robust perform compar
consensu expect believ vertex geograph revenu mix continu
heavili weight us due continu resist payer
europ dynam put current consensu medium-term revenu estim risk
probabl success tripl combin valuat account
full expect valu cf portfolio well risk-adjust opportun compani
effort antitrypsin defici aatd even posit view new dcf
valuat incorpor sustain oper margin
requir consider disciplin compani reput frugal
incorpor premium price target recogn vertex
might one attract larg cap growth asset sector howev view
reason acquisit premium would put compani cost nearli like
difficult pill swallow dilution-avers larg compani
revenu beat driven strong symdeko uptak continu orkambi expans
vertex total cf product revenu beat consensu beat
forecast global symdeko sale ahead estim
ahead consensu grow sequenti orkambi biggest surpris grow
qoq like due increment progress secur reimburs eu countri well
recent approv label expans younger patient beyond indic symdeko
appear cannib orkambi occur quickli expect clearli
symdeko ad increment penetr patient sale kalydeco
consensu estim
higher revenu lower oper expens drive ep beat gross margin
slightli lower consensu estim vertex non-gaap total oper
expens consensu forecast non-gaap
expens consensu estim non-gaap
sg higher consensu estim increas
yoy oper expens reflect inclus partnership payment kymera
therapeut compani tax rate line consensu
slightli lower estim higher absolut yoy basi due releas
compani valuat allow major defer tax asset non-gaap
dilut ep easili beat consensu estim
guidanc updat back symdeko beat vertex rais full year product
revenu guidanc higher prior estim
consensu non-gaap sg expens guidanc
increas reflect addit payment
crispr expect second-half non-gaap tax rate guidanc
unchang compani note major compani tax provis non-
cash expens nol fulli deplet
reimburs major eu countri progress remain hope resolut
franc less visibl uk manag suggest reimburs discuss
franc uk still on-going optimist natur pace
discuss franc well prospect triple-therapi approv prod hesit countri
secur reimburs agreement prospect reimburs uk still seem
remot particularli context volatil polit situat reimburs
germani remain solid manag estim penetr elig adult
cf popul alreadi achiev contribut major symdeko ex-u
sale ex-u sale account overal product sale includ total
kalydeco sale total orkambi sale symdeko sale quarter
potenti agreement franc could lead signific increas ex-u sale estim
given french patient current acceler treatment access
non cf pipelin gain interest manag provid extens commentari
promis earli stage clinic pipelin asset vertex antitrypsin pipelin serv
focal point analyst manag commentari compani explain
advanc two oral small molecul corrector
recent enter phase dose rang studi aatd patient two mutat follow
posit safeti toler pk data sad/mad studi manag anticip
provid phase data could signific catalyst correl
biomark clinic outcom support vertex assert serum level correct
protein correl benefici lung activ contrast therapeut approach
oligonucleotid replac therapi could compound
simultan treat liver lung patholog vertex second corrector
recent move phase develop consist vertex strategi
mitig risk test multipl compound similar therapeut target compani
also present first data anoth novel drug compound oral small
molecul inhibitor function preclin data suggest could reduc proteinuria
patient focal segment glomerulosclerosi fsg homozyg
mutat fsg repres attract opportun vertex given strong genet basi
well establish phenotyp compani estim address patient
us alon molecul advanc clinic rapidli manag believ
phase proof-of-concept studi could occur earli pend success outcom
recent initi phase studi use proteinuria endpoint trial seem
reason us could acceler drug develop timelin increas probabl
success overal includ vertex program forecast valuat
compani progress pivot trial poc trial could caus us incorpor valu
program model
cf revenu forecast increas base strong trend price target increas
updat revenu expens forecast base recent quarter
commentari total revenu forecast increas remain larg
unchang increas forecast symdeko rel
short term model transit tripl combin signific
increment revenu continu forecast total revenu grow
year revis forecast consensu
later year base compani burgeon develop portfolio
increas forecast year beyond result total oper
expens forecast increas later year adjust
share count forecast compani newli announc small share repurchas base
chang pro-forma dilut ep estim significantli increas year
materi recent consensu estim higher
recent consensu later year estim larg unchang
significantli recent consensu revis price target
maintain market perform rate vrtx stock
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl higher growth larg cap biopharmaceut compani price sale
multipl mid larg cap high growth biopharmaceut compani discount cash
flow dcf use current averag high growth larg cap biopharma multipl ep
nvo azn appli current ep estim discount back
year compani cost equiti give valu one year use averag
high growth larg cap biotech price-to-revenu multipl sale
appli revenu estim post-tripl
discount back year compani cost equiti give valu one year
lastli dcf valuat given wacc termin cash flow growth rate
give present valu averag three method current price target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit kalydeco orkambi
compani main product today major risk disappoint delay failur
compani develop regulatori file novel tripl combin medicin
cystic fibrosi risk includ continu lack access reimburs vertex
medicin acceler success develop altern modul cftr
altern approach treat cf gene therapi final compani histori
spend much potenti earn expens diversifi acquisit could undermin
futur expect valu compani cf portfolio opportun better-than expect
perform includ realiz signific revenu compani current cf dual
combin market outsid us well acceler clinic develop tripl
sale non-gaap
non-gaap interest expens net
share count period basic
share count period dilut
guidanc
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
brand
type event
event trial detail
date known
up/down
expect
ema file cf patient year old
nda file cf patient year old
report clinic data peopl two
mutat
evalu abil reduc protein
level urin
svb leerink llc research compani file
million
product sale po adjust
tripl combin kalydeco second corrector full year sale
total product sale book
product sale po adjust
total product sale book
svb leerink llc research compani file
million
product sale direct product sale vertex
sale
forma tax excl nol benefit cash
 total revenu
sg total revenu
tax rate note differ pro forma due nol benefit cash
svb leerink llc partner research compani file
analysi stock price svb leerink target
method higher growth large-cap healthcar ep multipl svb leerink normal
current averag growth larg cap biopharma multipl ep nvo azn
svb leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
svb leerink llc research compani file factset
